Filtered By:
Drug: Taxotere
Therapy: Neoadjuvant Chemotherapy Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 156 results found since Jan 2013.
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins
Cancer Res Commun. 2023 Aug 15;3(8):1551-1563. doi: 10.1158/2767-9764.CRC-22-0501. eCollection 2023 Aug.ABSTRACTTriple-negative breast cancer (TNBC) constitutes 10%-15% of all breast tumors. The current standard of care is multiagent chemotherapy, which is effective in only a subset of patients. The original objective of this study was to deploy a mass spectrometry (MS)-based kinase inhibitor pulldown assay (KIPA) to identify kinases elevated in non-pCR (pathologic complete response) cases for therapeutic targeting. Frozen optimal cutting temperature compound-embedded core needle biopsies were obtained from 43 patients wit...
Source: Cell Research - August 17, 2023 Category: Cytology Authors: Junkai Wang Alexander B Saltzman Eric J Jaehnig Jonathan T Lei Anna Malovannaya Matthew V Holt Meggie N Young Mothaffar F Rimawi Foluso O Ademuyiwa Meenakshi Anurag Beom-Jun Kim Matthew J Ellis Source Type: research
Role of Adverse Events Supervision in Clinical Trials in Neoadjuvant Treatment of
Operable Stage III NSCLC
CONCLUSIONS: Camrelizumab combined with Docetaxel and Cisplatin can be used as a new adjuvant treatment for operable stage III NSCLC. Through the observation and control of AEs, treatment measures can be taken in time to reduce further complications, ensure patient' safety, and ensure the authenticity, scientificity and reliability of clinical trial data.PMID:37488083 | DOI:10.3779/j.issn.1009-3419.2023.102.23
Source: Cancer Control - July 24, 2023 Category: Cancer & Oncology Authors: Yun Zhang Shuang Zhou Wentao Tao Rong Li Source Type: research
Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
CONCLUSION: This study reports real-world evidence showing similar pCR and EFS outcomes with treatment regimens with and without AC and raises awareness of possible overtreatment and long-term toxicity in some patients with HER2+ EBC with the use of AC.PMID:37479867 | DOI:10.1007/s40261-023-01291-6
Source: Clinical Breast Cancer - July 21, 2023 Category: Cancer & Oncology Authors: In ês Soares de Pinho Paulo Luz Lucy Alves Raquel Lopes-Br ás Vanessa Patel Miguel Esperan ça-Martins Lisa Gon çalves Ritas Freitas Diana Sim ão Maria Rold án Galnares Isabel Fernandes Silvia Artacho Criado Salvador Gamez Casado Jose Baena Ca ñada Source Type: research
S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy
CONCLUSION: These results reveal a novel function for S100A6 in downregulating MDM2, which directly enhances sensitivity to chemotherapy.PMID:37217945 | DOI:10.1186/s13058-023-01657-w
Source: Cell Research - May 22, 2023 Category: Cytology Authors: Mengxin Qi Xianglan Yi Baohui Yue Mingxiang Huang Sheng Zhou Jing Xiong Source Type: research
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
CONCLUSIONS: This real-life study indicates that adding P to NCT-H enables higher pCR than NCT-H in HER2+ BC, while pCR was associated with lower relapse and better EFS time.PMID:37083566 | DOI:10.1080/0284186X.2023.2202330
Source: Acta Oncologica - April 21, 2023 Category: Cancer & Oncology Authors: Ahmet Bilici Omer Fatih Olmez Muhammed Ali Kaplan Berna Oksuzoglu Ahmet Sezer Nuri Karadurmus Erdem Cubukcu Mehmet Ali Nahit Sendur Sercan Aksoy Dilek Erdem Gul Basaran Burcu Cakar Abdallah T M Shbair Cagatay Arslan Ahmet Taner Sumbul Sema Sezgin Goksu Ib Source Type: research
Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta-analysis, and meta-regression analysis
Cancer Med. 2023 Apr 20. doi: 10.1002/cam4.5930. Online ahead of print.ABSTRACTUterine leiomyosarcoma (uLMS) is an aggressive mesenchymal neoplasm associated with a poor prognosis. Systemic chemotherapy is the standard therapy for patients with uLMS. However, it is unclear which treatment regimen results in the most favorable clinical outcome. We performed a meta-analysis and meta-regression analysis to assess the efficiency of different treatments received by patients with advanced, metastatic, and relapsing uLMS by evaluating the objective response rate (ORR) and disease control rate (DCR) as primary endpoints. The frequ...
Source: Cancer Control - April 20, 2023 Category: Cancer & Oncology Authors: Iqra Ijaz Muhammad Naveed Shahzad Hossein Hosseinifard Shuya Liu Masoud Ostadi Sefidan Lubna Ejaz Kahloon Saber Imani Zhong Hua Yu Qin Zhang Source Type: research
